PLOS ONE | DOI:10.1371/journal.pone.0144057 December 14, 2015
Journal of Cancer Education
https://doi.org/10.1007/s13187-020-01935-7
Volume 2 · Supplement 4 · November 2016
ISSN 2055-66-40 – Print
Foreword
| ISSN 2055-66-59 – Online
www.viruseradication.com
Introducción
Capítulo A.1
The study on health facility preparedness for cholera outbreak response in Cameroon evaluates the ability of healthcare facilities in four cholera-prone districts to manage cholera outbreaks. The findings highlight significant weaknesses, including limited surveillance systems, inadequate access to ...water, poor sanitation, and lack of essential medical supplies such as Oral Rehydration Solution (ORS) and cholera case management guidelines. Many health facilities also lacked trained personnel and proper waste disposal systems, increasing the risk of disease spread within healthcare centers. The study underscores the urgent need for improved hygiene infrastructure, better training, and resource allocation to enhance outbreak response and reduce cholera-related mortality.
more
Further analysis of the 2011 Nepal Demographic and Health Survey
Further analysis of the 2011 Nepal Demographic and Health Survey
Global HIV Strategic Information Working Group
For Populations At Risk For HIV
BMC Pedaitrics. DOI: 10.1186/1471-2431-12-90
Noncommunicable diseases (NCDs) such as cancer, cardiovascular diseases, diabetes and chronic respiratory diseases and their risk factors are an increasing public health and development challenge in Turkey. This report provides evidence through three analyses that NCDs reduce economic output, and di...scusses potential options in response, outlining details of their relative returns on investment. An economic burden analysis shows that economic losses from NCDs are equivalent to 3.6% of gross domestic product. An intervention costing analysis provides an estimate of the funding required to implement a set of policy interventions for prevention and clinical interventions. A cost–benefit analysis compares these implementation costs with the estimated health gains and identifies which policy packages would give the greatest returns on investment.
more
Identified through evaluation of the response to pandemic (H1N1) 2009
Background: In 2015, 5.3 million babies died in the third trimester of pregnancy and first month following birth. Progress in reducing neonatal mortality and stillbirth rates has lagged behind the substantial progress in reducing postneonatal and maternal mortality rates. The benefits to prenatal an...d neonatal health (PNH) from maternal and child health investments cannot be assumed. Methods: We analysed donor funding for PNH over the period 2003–2013. We used an exhaustive key term search followed by manual review and classification to identify official development assistance and private grant (ODA+) disbursement records in the Countdown to 2015 ODA+ Database.
more
Nepal has made substantial progress in reducing under-five mortality and is on track to achieve Millennium Development Goal 4, but advances in neonatal health are less encouraging. The objectives of this study were to assess relative and absolute inequalities in neonatal mortality over time, and to ...review experience with major programs to promote neonatal health.
more
Research
BMJ 2014;349:g4643 doi: 10.1136/bmj.g4643 (Published 5 August 2014), 1-11
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f...or developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
more